Larimar Therapeutics (LRMR) Accumulated Expenses (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Accumulated Expenses for 14 consecutive years, with $25.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 18.81% year-over-year to $25.4 million; the trailing twelve-month figure through Jun 2026 stood at $25.4 million (up 18.81% YoY), and the FY2025 full-year result was $58.5 million, up 180.16% from the prior year.
• Accumulated Expenses eased to $25.4 million in Q2 2026 per LRMR's latest filing, from $58.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $58.5 million in Q4 2025 and bottomed at $4.4 million in Q2 2023.
• Historically, Accumulated Expenses has averaged $15.9 million across 5 years, with a median of $10.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 35.84% in 2023, then surged 295.1% in 2024.
• Over 5 years, Accumulated Expenses stood at $8.4 million in 2022, then dropped by 12.16% to $7.4 million in 2023, then surged by 182.59% to $20.9 million in 2024, then soared by 180.16% to $58.5 million in 2025, then plunged by 56.62% to $25.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $25.4 million, $58.5 million, and $32.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.